GlassScriptPhysician profile
Jose D Diaz
NPI 1265813810
$7,329.42
in general payments reported to CMS, 2019-2025
24 companies · $1,218 in 2025
The $1,218 reported for 2025 was more than what 81% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $727 · 2020: $557 · 2021: $814 · 2022: $1,747 · 2023: $1,272 · 2024: $995 · 2025: $1,218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,484.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,484.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,184.79 | 2022-2024 | Trelegy Ellipta |
| Alimera Sciences, INC. | $1,076.34 | 2020-2024 | Yutiq, Iluvien |
| Alcon Vision LLC | $1,005.82 | 2019-2025 | Clareon Panoptix Pro, Constellation |
| Regeneron Healthcare Solutions, INC. | $556.83 | 2021-2025 | Eylea Hd, Eylea |
| Astellas Pharma US INC | $506.41 | 2023-2025 | Izervay |
| Genentech USA, INC. | $440.01 | 2021-2025 | Vabysmo, Susvimo |
| Mallinckrodt Hospital Products INC. | $326.61 | 2023-2025 | Acthar |
| Apellis Pharmaceuticals, INC. | $311.81 | 2022-2025 | Syfovre |
| Eyepoint US, INC. | $303.75 | 2021-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $237.07 | 2020-2022 | |
| Abbvie INC. | $218.72 | 2022-2025 | Ozurdex |
| Dutch Ophthalmic, USA | $147.70 | 2022 | |
| Bausch & Lomb Americas INC. | $122.33 | 2022-2024 | Xiidra |
| Tarsus Pharmaceuticals, INC. | $121.87 | 2025 | Xdemvy |
| Rayner Intraocular Lenses Limited | $119.68 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coherus Oncology, INC. | $117.39 | 2022 | |
| Coopervision INC. | $107.38 | 2025 | Myday Contact Lens |
| Kala Pharmaceuticals, INC. | $94.47 | 2021 | |
| Allergan, INC. | $91.87 | 2020 | |
| Lkc Technologies, INC. | $90.09 | 2025 | |
| Regeneron Pharmaceuticals, INC. | $77.65 | 2022 | |
| Spark Therapeutics, INC. | $27.91 | 2022 | |
| Ani Pharmaceuticals, INC. | $25.08 | 2025 | Iluvien |
| Philips North America LLC | $17.84 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Diaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.